Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1) - Strand, Vibeke; Mease, Philip; Gossec, Laure; Elkayam, Ori; van den Bosch, Filip; Zuazo, James; Pricop, Luminita; Mpofu, Shephard (Annals of the rheumatic diseases, 2017)
Keywords: Adult; Aged; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized; Arthritis, Psoriatic - drug therapy; Clinical outcomes; Drug Administration Schedule; Female; Humans; Immunologic Factors - administration & dosage; Immunologic Factors - therapeutic use; Injections, Intravenous; Injections, Subcutaneous; Life Sciences; Male; Middle Aged; Patient Reported Outcome Measures; Psoriatic arthritis; Quality of Life; Severity of Illness Index; Treatment Outcome; Patient perspective; Treatment; Quality Indicators; Psoriatic Arthritis